Kymab Ltd.

Frontier Medicines Corp. has raised $235.5m in venture capital to date, including an $80m series C round unveiled on 22 February, although this latest financing is slightly smaller than its $88.5m se

The biotech sector may be in the middle of a rough patch when it comes to financing but a start-up from Allan Bradley’s laboratory at Cambridge University called T-Therapeutics, which has the ambitiou

Sanofi has unveiled positive Phase II data from amlitelimab in atopic dermatitis, backing up its belief that it could be a first and best-in-class novel therapy targeting the OX40 ligand. The candida

Just five months after bagging US rights to Provention Bio, Inc. 's type 1 diabetes therapy Tzield, Sanofi has decided it wants to buy the whole company and is prepared to pay a huge premium to do